Enhanced MAGE-A4 targeting T cell receptor (TCR) and application thereof

By combining CD8α and CD8β with TCR targeting MAGE-A4 to T cells and NKT cells, the problem of insufficient killing function of MAGE-A4-expressing tumor cells in the prior art was solved, and its killing and amplification capabilities were significantly enhanced. , achieving stronger anti-tumor effect.

CN118930655APending Publication Date: 2024-11-12KESHIHUA (NANJING) BIOTECHNOLOGY CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410538547.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-04-30
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing T cell therapy has limitations in its anti-tumor effect, especially its killing function for MAGE-A4-expressed tumor cells, and its long-term proliferation and clearance ability are weak.

Method used

By combining CD8α and CD8β elements with TCR targeting MAGE-A4, they are transferred to immune cells (T cells and NKT cells) to enhance their killing function and amplification ability to tumors, and transduce them with lentiviral vectors. And the effect was verified through CD107a degranulation experiment and in vitro killing experiment.

Benefits of technology

Significantly enhanced the killing ability and amplification function of T cells and NKT cells on MAGE-A4-positive tumor cells. CD8αβ-TCR NKT and CD8αα-TCR NKT cells showed higher CD107a+ ratio and killing ability after stimulation, and had stronger The long-term proliferation potential significantly inhibits the growth of tumor cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930655A_ABST
    Figure CN118930655A_ABST
Patent Text Reader

Abstract

The invention discloses an enhanced T cell receptor (TCR) for targeting MAGE-A4 and an application of the T cell receptor (TCR). CD8 alpha alpha and CD8 alpha beta are connected with TCR in series to construct a lentiviral vector, and T cells or NKT cells are transduced to prepare the cell preparation. The result shows that the amplification capacity of the CD8 alpha beta-TCR or CD8 alpha alpha-TCR cell preparation targeting MAGE-A4 after antigen stimulation and the killing capacity of the CD8 alpha beta-TCR or CD8 alpha alpha-TCR cell preparation on target cells (HLA-A02: 01 + MAGE-A4 +) are both higher than those of a corresponding single TCR cell preparation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of cell immunotherapy, in particular to the field of T cell therapy, and specifically to an enhanced T cell receptor (TCR) targeting MAGE-A4 and applications thereof. Background Art

[0002] Immunotherapy achieves the effect of curing cancer by enhancing the function of the patient's immune system and using immune cells to eliminate cancer cells in the body. Cell therapy is an adoptive therapy that transfers T cells that are specifically reactive to target cell antigens into the patient's body so that they can act on target cells. The T cell receptor (TCR) is a membrane protein on the surface of T cells that can recognize antigenic short peptides on the surface of corresponding target cells. In the immune system, through the combination of antigenic short peptide-specific TCR and short peptide-major histocompatibility complex (pMHC complex), T cells and antigen presenting cells (APC) are in direct physical contact, and then other cell membrane surface molecules of both T cells and APCs interact, causing a series of subsequent signal transmission, so that T cells with different antigen specificities can exert immune effects on their target cells.

[0003] Natural killer T (NKT) cells, also known as natural killer T cells, are a special type of lymphocytes between innate immunity and acquired immunity, and are considered to be the fourth type of lymphocytes [NatRev Immunol., 2010; 10: 272-277]. NKT cells express both TCR and NK cell receptors. According to the currently accepted system nomenclature, NKT cells are mainly divided into three types, type I, type II and type III; type I NKT is also called invariant NKT (iNKT for short). One of the characteristics of iNKT cells is that they can recognize α-galactosylceramide (αGalCer); another characteristic is that the variable region of the alpha chain of iNKT TCR is a constant amino acid sequence of V24a-Jα18; the third characteristic is that compared with the TCR of MHC-restricted T cells, the Beta chain diversity of iNKT TCR is very low, so the overall diversity of iNKT TCR is very low, which is suitable for allogeneic immune cell therapy. Therefore, the present invention explores the development of TCRNKT universal cell therapy for tumors and finds that TCR NKT has significant anti-tumor effects. In addition, compared with TCR NKT, CD8αCD8α-TCR NKT and CD8αCD8β-TCRNKT have better killing and amplification functions.

[0004] The patent of this invention adds CD8α and CD8β elements and combines them with TCR targeting MAGE-A4 to transfer them into immune cells (T cells and NKT cells). Compared with the simple transfer of TCR into immune cells, it can significantly enhance the expansion of immune cells and their tumor-killing function. Summary of the invention

[0005] The present invention discloses a T cell receptor, which comprises a TCRα domain, a TCRβ domain, a CD8α domain and / or a CD8β domain, and a linker domain connecting the domains, wherein the sequence of the CD8α domain is at least 90% identical to SEQ ID NO: 20, and the sequence of the CD8β domain is at least 90% identical to SEQ ID NO: 24.

[0006] Preferably, the T cell receptor is a modified T cell receptor.

[0007] Preferably, the T cell receptor is in single chain form.

[0008] Preferably, the type of the T cell receptor is TCRα-L-TCRβ, and L is a linker domain or a linker sequence.

[0009] Preferably, the T cell receptor comprises a TCRα domain, a TCRβ domain, a CD8α domain and a CD8α domain, and a linker domain connecting the domains.

[0010] Preferably, the T cell receptor comprises a TCRα domain, a TCRβ domain, a CD8α domain and a CD8α domain in sequence, and a linker domain connecting the domains.

[0011] Preferably, the T cell receptor comprises a TCRα domain, a TCRβ domain, a CD8α domain and a CD8β domain, and a linker domain connecting the domains.

[0012] Preferably, the T cell receptor comprises a TCRα domain, a TCRβ domain, a CD8α domain and a CD8β domain in sequence, and a linker domain connecting the domains.

[0013] Preferably, the TCRα domain comprises the Vα region, the Jα region and the mCα region in sequence, and the TCRβ domain comprises the Vβ region, the Dβ region, the Jβ region and the mCβ region in sequence.

[0014] Preferably, the TCRα domain is composed of the Vα region, the Jα region and the mCα region in sequence, and the TCRβ domain is composed of the Vβ region, the Dβ region, the Jβ region and the mCβ region in sequence.

[0015] Preferably, the sequence of the Vα region is shown as SEQ ID NO:2, the sequence of the Jα region is shown as SEQ ID NO:4, and the sequence of the mCα region is shown as SEQ ID NO:6.

[0016] Preferably, the sequence of the Vβ region is shown as SEQ ID NO:10, the sequence of the Dβ region is shown as SEQ ID NO:12, the sequence of the Jβ region is shown as SEQ ID NO:14, and the sequence of the mCβ region is shown as SEQ ID NO:16.

[0017] Preferably, the sequence of the CD8α domain is shown as SEQ ID NO:20, and the sequence of the CD8β domain is shown as SEQ ID NO:24.

[0018] Preferably, the linker domain is selected from the sequence shown in SEQ ID NO:8, SEQ ID NO:18 or SEQ ID NO:22.

[0019] Preferably, the sequence of the linker domain between the TCRα domain and the TCRβ domain is as shown in SEQ ID NO:8.

[0020] Preferably, the linker domain sequence between the TCRβ domain and the CD8α domain is as shown in SEQ ID NO:18.

[0021] Preferably, the sequence of the linker domain between the CD8α domain and the CD8α domain is as shown in SEQ ID NO:22.

[0022] Preferably, the linker domain sequence between the CD8α domain and the CD8β domain is as shown in SEQ ID NO:22.

[0023] Preferably, the nucleotide sequences of CDR1, CDR2 and CDR3 contained in the TCRα domain are ACCTCCGAGAACAACTACTAC (SEQ ID NO: 25), AGGAGGCCTACAAGCAACAGAAC (SEQ ID NO: 26), and GCCACCCACAGCGGCGCCGGCAGCTACCAGCTGACC (SEQ ID NO: 27), respectively; The nucleotide sequences of CDR1, CDR2 and CDR3 contained in the TCRβ domain are AGCGAGCACAATCGG (SEQ ID NO: 31), TTCCAGAATGAAGCCCAG (SEQ ID NO: 32), and GCCAGCTCTGCTCCTGGCTATAACGAGCAGTTT (SEQ ID NO: 33), respectively.

[0024] Preferably, the amino acid sequences of CDR1, CDR2 and CDR3 contained in the TCRα domain are TSENNYY (SEQ ID NO: 28), QEAYKQQN (SEQ ID NO: 29), and ATHSGAGSYQLT (SEQ ID NO: 30), respectively; wherein, the amino acid sequences of CDR1, CDR2 and CDR3 contained in the TCRβ domain are SEHNR (SEQ ID NO: 34), FQNEAQ (SEQ ID NO: 35), and ASSAPGYNEQF (SEQID NO: 36), respectively.

[0025] The present invention discloses an isolated polynucleotide encoding the T cell receptor.

[0026] Preferably, the nucleotide sequence encoding the CD8α domain is at least 85% identical to SEQ ID NO:19.

[0027] Preferably, the nucleotide sequence encoding the CD8β domain is at least 85% identical to SEQ ID NO:23.

[0028] Preferably, the nucleotide sequence encoding the CD8α domain is shown as SEQ ID NO:19.

[0029] Preferably, the nucleotide sequence encoding the CD8β domain is shown as SEQ ID NO:23.

[0030] Preferably, the Vα region comprises the nucleotide sequence shown in SEQ ID NO:1, the Jα region comprises the nucleotide sequence shown in SEQ ID NO:3, and the mCα region comprises the nucleotide sequence shown in SEQ ID NO:5.

[0031] Preferably, the nucleotide sequence encoding the TCR Vα region is shown as SEQ ID NO: 1, the nucleotide sequence encoding the TCR Jα region is shown as SEQ ID NO: 3, and the nucleotide sequence encoding the mCα region is shown as SEQ ID NO: 5.

[0032] Preferably, the Vβ region comprises the nucleotide sequence shown in SEQ ID NO:9, the Dβ region comprises the nucleotide sequence shown in SEQ ID NO:11, the Jβ region comprises the nucleotide sequence shown in SEQ ID NO:13, and the mCβ region comprises the nucleotide sequence shown in SEQ ID NO:15.

[0033] Preferably, the nucleotide sequence encoding the Vβ region is shown as SEQ ID NO:9, the nucleotide sequence encoding the Dβ region is shown as SEQ ID NO:11, the nucleotide sequence encoding the Jβ region is shown as SEQ ID NO:13, and the nucleotide sequence encoding the mCβ region is shown as SEQ ID NO:15.

[0034] The present invention discloses a vector, which comprises the polynucleotide.

[0035] Preferably, the vector is a viral vector or a homologous recombination repair gene knock-in vector.

[0036] Preferably, the vector is selected from plasmid, retroviral vector and lentiviral vector, transposon vector, ssDNA, dsDNA and the like.

[0037] Preferably, the vector is a retroviral vector or a lentiviral vector.

[0038] Preferably, the vector is long single-stranded DNA (ssDNA), double-stranded DNA (dsDNA), or mini circular DNA (circledsDNA).

[0039] The present invention discloses a cell, which comprises the vector.

[0040] The present invention discloses a cell, which presents the T cell receptor.

[0041] The present invention discloses a cell, which comprises the T cell receptor.

[0042] Preferably, the cell is an isolated cell or a naturally occurring cell.

[0043] Preferably, the cells are selected from lymphocytes.

[0044] Preferably, the lymphocytes are immune effector cells, and the scope is not limited to iPSC-derived cells.

[0045] Preferred ones include, but are not limited to, cytotoxic T lymphocytes (CTL), CD8+T cells, CD4+T cells, natural killer (NK) cells, natural killer T (NKT) cells, and γ / δ-T cells.

[0046] Preferably, the T cell receptor further comprises at least one molecular marker.

[0047] The present invention discloses a method for producing a T cell receptor, the method comprising: 1) incubating the cells; 2) Purifying the T cell receptor.

[0048] The invention discloses a T cell receptor, which is prepared by adopting the method described above.

[0049] The present invention discloses a composition, which comprises one or more of the following: 1) According to the T cell receptor; 2) according to the polynucleotide; 3) According to the vector; 4) According to the cells described.

[0050] Preferably, the composition further comprises a pharmaceutically acceptable carrier or excipient.

[0051] Preferably, the composition is a medicament.

[0052] The present invention discloses a kit, which comprises one or more of the following: 1) According to the T cell receptor; 2) according to the polynucleotide; 3) According to the vector; 4) According to the cells described.

[0053] The present invention discloses use of the T cell receptor, the polynucleotide, the vector or the cell in preparing a composition for treating cancer.

[0054] Preferably, the cancer is a tumor.

[0055] Preferably, the cancer is MAGE-4 positive.

[0056] Preferably, the cancer is selected from melanoma, lung cancer, gastric cancer, esophageal cancer, and human brain glioblastoma multiforme.

[0057] The present invention discloses the use of CD8α and CD8β in preparing a composition for improving the killing ability of T cells. CD8α and CD8β are constructed into T cell receptors or CD8α and CD8β are co-expressed with T cell receptors in T cells. The sequence of the CD8α domain is at least 90% identical to SEQ ID NO: 20, and the sequence of the CD8β domain is at least 90% identical to SEQ ID NO: 24.

[0058] Preferably, the “CD8α and CD8β” are selected from a combination of “CD8α and CD8α” or a combination of “CD8α and CD8β”.

[0059] Preferably, the CD8α and CD8β are constructed into a T cell receptor, which comprises a TCRα domain, a TCRβ domain, a CD8α domain and / or a CD8β domain, and a linker domain connecting the domains. Preferably, the T cell receptor comprises a TCRα domain, a TCRβ domain, a CD8α domain and a CD8α domain in sequence, and a linker domain connecting the domains.

[0060] Preferably, the T cell receptor comprises a TCRα domain, a TCRβ domain, a CD8α domain and a CD8β domain, and a linker domain connecting the domains.

[0061] The present invention prepares a modified TCR by co-expressing CD8α and CD8β with TCR, prepares a lentiviral vector of TCR molecular cloning, and transduces NKT cells to prepare TCR-NKT cells. Then, the tumor killing effect of TCR-NKT cells is evaluated by CD107a degranulation assay and in vitro cytotoxicity assay. The results show that: NKT cells transferred into TCR have a significant tumor killing effect; among them, the CD107a+ ratio of CD8αβ-TCR NKT and CD8αα-TCR NKT cells after being stimulated by double positive target cells (HLA-A02:01+MAGE-A4+) is significantly higher than that of TCR NKT cells; CD8αβ-TCR NKT and CD8αα-TCR NKT cells have stronger expansion ability and killing ability against target cells than TCRNKT cells. TCR NKT cells with CD8αα or CD8αβ can better maintain the ability to kill target cells after being stimulated by target cells than TCR NKT cells.

[0062] Therefore, TCR NKT cells co-expressing CD8αβ or CD8αα can be considered to have stronger potential for long-term proliferation and elimination of tumor cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0063] Figure 1 .Schematic diagram of the structure of TCR molecule.

[0064] Figure 2 .NKT purity and TCR positive test results.

[0065] Figure 3.Detection of HLA-A02 expression in target cells.

[0066] Figure 4 .Different TCR NKT cell CD107a release results.

[0067] Figure 5 .In vitro killing results of NKT cells with different TCRs.

[0068] Figure 6 . Determination of proliferation of NKT cells with different TCRs after repeated stimulation.

[0069] Figure 7 .Determination of killing ability of different TCR-NKT cells after repeated stimulation.

[0070] Figure 8 .The inhibitory effects of different TCR NKT cells on tumor cells in vivo.

[0071] Fig. 9 . The inhibitory effects of different TCR T cells on tumor cells in vivo. DETAILED DESCRIPTION

[0072] The specific implementation of the present invention is described in detail below in conjunction with the accompanying drawings. It should be understood that the specific implementation described here is only used to illustrate and explain the present invention, and is not used to limit the present invention.

[0073] Example 1 Vector Construction Schematic diagram of the TCR molecular structure targeting MAGE-A4 Figure 1 shown.

[0074] Among them, TCR Vα nucleic acid sequence: ATGACACGAGTTAGCTTGCTGTGGGCAGTCGTGGTCTCCACCTGTCTTGAATCCGGCATGGCCCAGACCGTGACCCAGAGCCAACCTGAGATGAGCGTGCAGGAGGCCGAGACAGTGACCCTGAGCTGCACATACGACACCTCCGAGAACAACTACTACCTGTTTTG GTACAAGCAGCCTCCATCTAGACAGATGATCCTGGTGATCCGGCAGGAGGCCTACAAGCAACAGAACGCCACCGAGAACCGGTTCAGCGTCAACTTTCAAAAGGCTGCTAAGAGCTTCAGCCTGAAGATCTCTGATAGCCAGCTGGGAGATACCGCCATGTACTTC. (SEQ ID NO:1).

[0075] TCR Vα amino acid sequence: MTRVSLLWAVVVSTCLESGMAQTVTQSQPEMSVQEAETVTLSCTYDTSENNYYLFWYKQPPSRQMILVIRQEAYKQQNATENRFSVNFQKAAKSFSLKISDSQLGDTAMYF. (SEQ ID NO:2).

[0076] TCR Jα nucleic acid sequence: TGCGCCACCCACAGCGGCGCCGGCAGCTACCAGCTGACCTTCGGCAAGGGCACCAAGCTGAGCGTCATCCCC. (SEQ ID NO:3) TCR Jα amino acid sequence: CATHSGAGSYQLTFGKGTKLSVIP. (SEQ ID NO:4).

[0077] TCR mCα nucleic acid sequence: AACATCCAGAACCCTGAGCCTGCCGTGTACCAGCTTAAAGATCCTAGAAGCCAAGACTCTACCCTGTGCCTGTTCACCGACTTCGACAGCCAGATCAACGTCCCCAAGACCATGGAAAGTGGCACATTCATCACAGATAAGACCGTGTTGGACATGAAAGCCATGGACAGCAAGAGCAATGGCGCCATCGCCTGGAGCAACCAGACATCCTTCACCTGTCAGGACATCTTCAAGGAGACAAACACCACCTATCCTAGCAGCGACGTGCCGTGCGACGCCACGCTGACAGAGAAATCCTTCGAGACAGATATGAACCTGAACTTCCAGAACCTGAGCGTGATGGGCCTCAGAATCCTGCTGCTGAAGGTGGCCGGATTTAACCTGCTGATGACCCTGAGGCTTTGGTCCAGC. (SEQ ID NO:5).

[0078] TCR mCα amino acid sequence: NIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTMESGTFITDKTVLDDMKAMDSKSNGAIAWSNQTSFTCQDIFKETNTTYPSSDVPCDATLTEKSFETDMNLNFQNLSVMGLRILLLKVAGFNLLMTLRLWSS。(SEQ IDNO:6)。

[0079] 2A1: AGAGCCAAGCGGAGCGGCAGCGGCGCTACCAACTTCTCTCTGCTGAAACAGGCTGGCGACGTGGAGGAAAATCCTGGCCCT。(SEQ ID NO:7)。

[0080] 2A1 Connection: RAKRSGSGATNFSLLKQAGDVEENPGP。(SEQ ID NO:8)。

[0081] TCR Vβ: ATGGGCACCAGCCTCCTCTGCTGGATGGCCCTGTGTCTCCTGGGGGCAGATCACGCACCGGCGTGTCTCAAAACCCTCGGCATAAGATCACCAAGCGGGGCCAGAACGTGACCTTTCAGATGTGACCCCATCAGCGAGCAATCGGCTGTACTGGTATAGACA GACCCTGGGGCAGGGACCAGAGTTCCTGACTTACTTCCAGAATGAAGCCCAGCTGGAAAAATCTAGACTGCTGTCCGATAGGTTCAGCGCCGAAAGACCTAAGGGCAGCTTCTCTACACTGGAGATTCAGAGAACCGAGCAGGCGATTCTGCTATGTACCTG。(SEQ ID NO:9)。

[0082] TCR Vβ is: MGTSLLCWMALCLLGADHADTGVSQNPRHKITKRGQNVTFRCDPISEHNRLYWYRQTLGQGPEFLTYFQNEAQLEKSRLLSDRFSAERPKGSFSTLEIQRTEQGDSAMYL。(SEQ ID NO:10)。

[0083] TCR Dβ: TGTGCCAGCTCTGCTCCTGGCTATAACGAGCAGTTT。(SEQ ID NO:11)。

[0084] TCR Dβ amino acid sequence: CASSAPGYNEQF。(SEQ ID NO:12)。

[0085] TCR Jβ nucleic acid sequence: TTCGGCCCCGGAACCAGACTGACAGTGCTG。(SEQ ID NO:13)。

[0086] TCR Jβ amino acid sequence: FGPGTRLTVL。(SEQ ID NO:14)。

[0087] TCR mCβ nucleic acid sequence: GAAGACCTGAGAAATGTGACACCACCTAAGGTGAGCCTGTTTGAGCCCAGCAAGGCCGAGATCGCCAACAAGCAGAAAGCAACCCTGGTGTGCCTGGCCAGAGGCTTCTTTCCAGACCACGTGGAACTGAGCTGGTGGGTGAACGGCAAGGAAGTACACAGCGGAGTGAGCACCGACCCTCAGGCCTACAAAGAGTCTAACTACTCCTACTGCCTGTCTAGCCGGCTGAGAGTGAGCGCCACATTTTGGCACAATCCCCGGAATCACTTCCGCTGCCAAGTGCAGTTCCACGGCCTGTCCGAAGAGGATAAGTGGCCTGAAGGCTCTCCTAAGCCCGTGACACAGAACATCTCTGCCGAAGCCTGGGGAAGAGCCGACTGCGGCATCACCAGCGCTAGCTACCAGCAGGGCGTTCTGAGCGCCACCATCCTGTACGAGATTCTGCTGGGCAAGGCCACACTGTACGCCGTGTTAGTATCCACCCTGGTGGTGATGGCCATGGTGAAGAGAAAGAACAGC。(SEQID NO:15)。

[0088] TCR mCβ amino acid sequence: EDLRNVTPPKVSLFEPSKAEIANKQKATLVCLARGFFPDHVELSWWVNGKEVHSGVSTDPQAYKESNYSYCLSSRLRVSATFWHNPRNHFRCQVQFHGLSEEDKWPEGSPKPVTQNISAEAWGRADCGITSASYQQGVLSATILYEILLGKATLYAVLVSTLVVMAMVKRKNS. (SEQ ID NO:16).

[0089] 2A2 nucleic acid sequence: GGCAGCGGAGAGGGACGCGGCAGTCTGCTGACATGTGGTGACGTCGAAGAGAACCCTGGCCCT. (SEQID NO:17).

[0090] 2A2 amino acid sequence: GSGEGRGSLLTCGDVEENP. (SEQ ID NO:18).

[0091] CD8α nucleic acid: ATGGCCTTGCCAGTGACAGCTCTCTTGTTGCCTCTGGCACTGTTGTTGCACGCTGCTAGGCCAAGCCAGTTCAGGGTGTCTCCACTGGACAGAACTTGGAACCTCGGTGAGACAGTGGAACTGAAGTGCCAGGTGCTGTTGAGCAACCCTACATCTGGCTGCAGCTGGCTGTTCCAGCCTAGAGGTGCTGCCGCCTCTCCAACATTTCTGCTGTACCTGAGCCAGAACAAGCCAAAGGCTGCCGAAGGCCTGGACACACAGCGCTTCAGCGGCAAGAGGCTGGGTGACACATTTGTGCTGACCTTGAGCGATTTCCGAAGGGAGAACGAGGGCTATTACTTCTGCTCTGCTCTGTCCAACAGCATCATGTACTTTAGCCACTTCGTGCCAGTCTTTCTGCCTGCAAAGCCTACCACAACACCTGCTCCAAGACCACCTACTCCAGCACCTACAATCGCAAGCCAGCCTCTGAGCCTTAGACCTGAGGCTTGTAGACCTGCTGCCGGTGGTGCCGTGCACACCAGAGGCTTGGATTTCGCCTGCGACATCTACATCTGGGCACCTCTGGCTGGTACTTGTGGCGTTCTGCTGCTGTCTCTGGTGATCACTCTCTACTGCAACCACCGGAACAGACGCAGAGTCTGCAAATGCCCTAGGCCAGTGGTGAAGTCTGGCGACAAGCCTTCTCTCTCCGCTAGGTATGTG。(SEQ ID NO:19)。

[0092] CD8α Amino Acids: GPMALPVTALLLPLALLLHAARPSQFRVSPLDRTWNLGETVELKCQVLLSNPTSGCSWLFQPRGAAASPTFLLYLSQNKPKAAEGLDTQRFSGKRLGDTFVLTLSDFRRENEGYYFCSALSNSIMYFSHFVPVFLPAKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRNRRRVCKCPRPVVKSGDKPSLSARYV。(SEQ ID NO:20)。

[0093] 2A3 nucleic acid sequence: GCCACCAATTTCAGCCTTCTGAAGCAGGCAGGTGACGTGGAAGAGAATCCAGGTCCA。(SEQ ID NO:21)。

[0094] 2A3 amino acid sequence: ATNFSLLKQAGDVEENP。(SEQ ID NO:22)。

[0095] CD8β nucleic acid: ATGAGGCCTAGATTGTGGCTGCTTCTGGCAGCTCAGCTCACCGTGCTTCACGGTAACAGCGTGCTTCAGCAGACACCAGCCTACATCAAGGTGCAGACCAACAAGATGGTCATGCTGAGCTGTGAAGCCAAGATTAGCCTCAGCAACATGCGGATCTACTGGCTGAGGCAGAGGCAGGCTCCATCTTCTGACAGCCACCATGAATTTCTGGCATTGTGGGACTCCGCTAAGGGCACCATTCATGGCGAAGAGGTGGAGCAGGAGAAGATCGCTGTGTTCAGGGATGCCAGCCGGTTCATTCTGAACCTGACAAGCGTCAAACCTGAAGATTCCGGCATCTACTTCTGTATGATCGTGGGCTCTCCAGAACTGACCTTCGGCAAGGGCACTCAGTTGTCCGTGGTGGACTTTCTGCCAACTACCGCTCAGCCTACCAAGAAGTCCACCTTGAAGAAACGGGTGTGTAGACTGCCTAGGCCTGAGACACAGAAGGGCCCTCTCTGTTCACCAATCACACTGGGTTTGCTGGTGGCAGGTGTTCTGGTGCTGCTGGTGAGCCTGGGTGTGGCAATCCACCTGTGTTGCAGGCGACGGAGGGCAAGATTGCGGTTTATGAAGCAGTTCTATAAGTGA。(SEQ ID NO:23)。

[0096] CD8β Amino Acids: MRPRLWLLLAAQLTVLHGNSVLQQTPAYIKVQTNKMVMLSCEAKISLSNMRIYWLRQRQAPSSDSHHEFLALWDSAKGTIHGEEVEQEKIAVFRDASRFILNLTSVKPEDSGIYFCMIVGSPELTFGKGTQLSVVDFLPTTAQPTKKSTLKKRVCRLPRPETQKGPLCSPITLGLLVAGVLVLLVSLGVAIHLCCRRRRARLRFMKQFYK。(SEQ IDNO:24)。

[0097] Among them, the nucleotide sequences of CDR1, CDR2 and CDR3 contained in the TCRα domain are ACCTCCGAGAACAACTACTAC (SEQ ID NO: 25), AGGAGGCCTACAAGCAACAGAAC (SEQ ID NO: 26), and GCCACCCACAGCGGCGCCGGCAGCTACCAGCTGACC (SEQ ID NO: 27), respectively.

[0098] Among them, the amino acid sequences of CDR1, CDR2 and CDR3 contained in the TCRα domain are TSENNYY (SEQ ID NO: 28), QEAYKQQN (SEQ ID NO: 29), and ATHSGAGSYQLT (SEQ ID NO: 30), respectively.

[0099] The nucleotide sequences of CDR1, CDR2 and CDR3 contained in the TCRβ domain are AGCGAGCACAATCGG (SEQ ID NO: 31), TTCCAGAATGAAGCCCAG (SEQ ID NO: 32), and GCCAGCTCTGCTCCTGGCTATAACGAGCAGTTT (SEQ ID NO: 33), respectively.

[0100] Among them, the amino acid sequences of CDR1, CDR2 and CDR3 contained in the TCRβ domain are SEHNR (SEQ ID NO: 34), FQNEAQ (SEQ ID NO: 35), and ASSAPGYNEQF (SEQ ID NO: 36), respectively.

[0101] Overlap PCR was used to convert the above sequences into Figure 1 As shown, a total of 3 constructs were constructed. The PGK vector backbone was selected for double restriction digestion (BamHI-HF and SalI-HF), and the TCR and backbone were connected by recombination and transformed into competent E. coli (Stable3).

[0102] Outsource the sequencing of the recombinant plasmid and compare the sequencing results with your synthesized sequence to verify whether the sequence is correct.

[0103] After the sequencing was correct, the plasmid was extracted and purified using the Qiagen plasmid purification kit.

[0104] Example 2 Lentivirus packaging On the first day, 293TS cells should be less than 20 generations and have a viability greater than 97%. Inoculate 5×105 / ml into a 250ml breathable shake flask, add 50ml of culture medium to the 250ml breathable shake flask, mix thoroughly, and culture at 37℃, 130rpm, 6% CO2 for 72h.

[0105] On the fourth day, the 293TS cell density reaches 5-7×106 / ml; the cell viability is ≥90%, and transfection can be performed; prepare the plasmid complex, aspirate 10% of the basic culture medium of the total culture volume, and divide it equally into 2 centrifuge tubes or centrifuge cups, marked as "PEI" tube and "DNA" tube respectively.

[0106] Plasmid addition: The ratio of the four plasmids is pHi001:pHi002:pHi003:transfer=3:5:5:7. Aseptically add the four plasmids into the "DNA" tube, shake well, and let stand at room temperature for 5 minutes.

[0107] PEI addition: Calculate the amount of transfection reagent based on PEI:DNA=2:1, pipette the corresponding volume of PEIpro into the "PEI" tube, and shake well.

[0108] Mixing of transfection complex: After the DNA solution has finished standing, use a pipette to add the solution in the "PEI" tube to the "DNA" tube, shaking the "DNA" tube while adding. After all the solution is added, mix well and let stand at room temperature for 15 minutes.

[0109] Transfection: When the transfection complex is set aside, add the transfection reagent to the corresponding shake flask. Shake to mix well and return to the incubator for culture (culture conditions: 37°C, 130rpm, 6% CO2).

[0110] Post-transfection feeding: 6-8h after transfection, add 20% of the package volume of feed medium and 2% of the package volume of 200mM glutamine to each flask.

[0111] Virus collection: Collect the supernatant 48 hours after transfection.

[0112] Example 3 TCR NKT cell preparation The NKT cells in this example were extracted from peripheral blood mononuclear cells (PBMC) of healthy donors using Ficoll-PaqueTM PREMIUM (GE healthcare), and the PBMCs were enriched using an NKT cell sorting kit (Miltenyi Biotec, catalog number: 130-093-064) to obtain NKT cells.

[0113] Subsequently, the obtained NKT cells were inoculated into a 24-well plate at 1×106 cells / well, and NKT complete medium was added to 2 ml. The formula of the NKT complete medium used was: X-VIVO15 medium (Lonza, Catalog No.: BEBP02-054Q) + 5% CTSImmune Cell SR (Gibco, Catalog No.: A25961-01) + 1000 IU / ml IL2 (Beijing Shuanglu, Catalog No.: National Medicine Standard S19991007) + 300 IU / ml IL15 (ACRO, Catalog No.: GMP-L15H13) + 200 IU / ml IL21 (ACRO, Catalog No.: GMP-L21H25) PBMCs irradiated with 40 Gy γ-rays were taken out, centrifuged and resuspended in NKT culture medium, and 5 ug / mL αGalcer (abcam, catalog number: ab144262) was added. After mixing, the cells were placed in a 37°C, 5% CO2 incubator for pretreatment for 2 hours.

[0114] After pretreatment, NKT cells and γ-ray irradiated PBMC were mixed at a ratio of 1:5 and cultured in an incubator at 37°C and 5% CO2, and 200 IU / ml IL2 was added every other day.

[0115] Ten days later, the NKT cells were reactivated in the same manner. After the second activation culture, the NKT cells were transduced with lentivirus and centrifuged at 32°C, 2000g for 2 hours. After centrifugation, the cells were cultured in a 37°C, 5% CO2 incubator.

[0116] 24 h after infection, the cell suspension was aspirated and centrifuged at 400 g for 5 min.

[0117] After cell infection, the cell density was observed every day, and NKT culture medium was added in time to maintain the density of NKT cells at about 5×105 / ml.

[0118] Thus, TCR NKT cells infected with the TCR virus are obtained.

[0119] Example 4 Flow cytometry detection of purity and TCR expression of NKT cells after virus infection TCR NKT cells and NKT cells (control group) 72 hours after infection were collected by centrifugation, washed with wash buffer and the supernatant was discarded. The corresponding antibodies were added and incubated in the dark for 30 minutes, washed with wash buffer, resuspended, and finally the TCR positivity rate and NKT purity were detected by flow cytometry.

[0120] The test results of this embodiment show that Figure 2, the proportion of NKT cells is above 95%, and the TCR positivity rate is greater than 30%.

[0121] Example 5 In vitro functional verification of TCR NKT cells Selection of target cells: Target cells and negative control target cells are: HLA-A02:01+MAGE-A4+ double expression cell line as positive control target cells, HLA-A02:01+MAGE-A4- or HLA-A02:01-MAGE-A4+ single expression cell line and HLA-A02:01-MAGE-A4- double negative expression cell line as negative control target cells. HLA typing detection is performed by second-generation sequencing, and target expression detection is performed by qPCR. A375 cells are [HLA-A02:01+MAGE-A4+] double-positive cells, NCI-H1755 cells are [HLA-A02:01+ MAGE-A4+] double-positive cells; T98G cells are [HLA-A02:01+MAGE-A4-] single-positive cells; NUGC-4 cells are [HLA-A02:01+MAGE-A4-] single-positive cells; OE-19 cells are [HLA-A02:01+MAGE-A4-] single-positive cells; The results of HLA sequencing are shown in Table 1. The results of HLA-A02 MFI expression detection are shown in Table 1. Figure 3 As shown, the target cell detection results are summarized in Tables 1 and 2.

[0122] Table 1: Target cell HLA-A sequencing results

[0123] Table 2: Target cell HLA-A and expression detection results Cell Name HLA-A02:01 MAGE-A4 A375 + + T98G + - NCI-H1755 + + NUGC-4 + - OE19 + - TCR-based immunotherapy mainly utilizes CD8+T cells that recognize tumor antigens presented by class I HLA, and clones the TCR into a lentiviral vector, and clones the CD8αβ structure on the TCR into a lentiviral vector to transduce NKT cells. The function on its TCR NKT cells needs to be further confirmed and the TCR structure with the best activity needs to be screened. To this end, we prepared lentiviral vectors of these TCR molecular clones and transduced NKT cells to prepare TCR NKT cells. Then, the in vitro biological efficacy of TCR NKT cells was evaluated by CD107a degranulation assay and in vitro cytotoxicity assay. Through the functional verification of these TCR NKT levels, the TCR structure with ideal effectiveness and safety was finally screened.

[0124] (1) CD107a degranulation assay CD107a is a marker of intracellular microvesicles. When microvesicles loaded with granzymes fuse with the cell membrane, the amount of CD107a on the cell membrane will increase. When monensin is used to block its recovery, the intensity of microvesicle release can be quantitatively reflected. When TCR-NKT cells are stimulated by positive target cells, granzymes are released, and the activation of TCR-NKT cells can be determined by flow cytometry to detect the enhancement of CD107a.

[0125] HLA-A02:01+ / MAGE-A4+ [A375 (human malignant melanoma cells), NCI-H1755 (human lung cancer cells), NUGC-4 overexpressing MAGE-A4 (human gastric cancer cells), OE19 overexpressing MAGE-A4 (human esophageal cancer cells), T98G overexpressing MAGE-A4 (human glioblastoma multiforme cells)] were used as positive target cells; HLA-A02:01+ / MAGE-A4- [T98G (human glioblastoma multiforme cells)] was used as negative target cells; HLA-A02:01+ / MAGE-A4- [NUGC-4 (human gastric cancer cells)] was used as negative target cells.

[0126] CD107a degranulation experimental steps: The TCR-NKT cells and target cells to be tested were centrifuged at 500g for 5 min at room temperature, the supernatant was discarded, and the cells were resuspended in 1640 basal medium to 2×106 cells / mL. In a 96-well plate, add 100 μL of the TCR-NKT cells to be tested and 100 μL of the target cells, and mix well; Add 1 μL PE / Cy7 mouse anti-human CD107a antibody and 0.2 μL monensin to each well of cells, and then place in a cell culture incubator (37°C, 5% CO2) and incubate for 4 hours; After incubation, the cells were centrifuged at 600 g for 5 min at 4 °C, the supernatant was discarded, and the cells were washed twice with 200 μL PBS; Resuspend the cells with 100 μL PBS, and add 2 μL FITC anti mouse TCR and APC antihuman TCR Vα24 Jα18 antibodies respectively, mix well and incubate on ice in the dark for 20 min; After incubation, the cells were washed three times with 200 μL PBS, resuspended with 100 μL PBS, and detected by flow cytometry. Main samples and reagents: Target cells: A375, NCI-H1755, NUGC-4 overexpressing MAGE-A4, OE-19 overexpressing MAGE-A4, T98G overexpressing MAGE-A4, T98G, NUGC-4 PE / Cy5 mouse anti-human CD107a, BD, Cat. No. 561348 Monensin, BioLegend, Cat.No. 420701 FITC anti human TCRβ chain ,Biolegend , Cat. No. 109206 Experimental results: Different TCR NKT cells were obtained by lentiviral transduction. After culturing the TCR-NKT cells in vitro for 20-25 days, CD107a degranulation experiment was performed. The TCR-NKT cells to be tested were co-incubated with target cells, monensin and CD107a antibody for 4 hours. The cell density of TCR-NKT cells and target cells was 2×10 6 cells / mL. The samples were then labeled with mTCR antibodies and TCR Vα24 Jα18 antibodies and flow cytometry was performed. In the Flowjo software, the live cell gate (P1) was selected in the scatter plot to remove cell debris; the cells in the P1 gate were analyzed and the single scattered cell gate (P2) was selected; then, TCR Vα24 Jα18-positive cells (ie, NKT-positive cells) were further selected in the P2 gate, and finally, in the P3 gate, the proportion of CD107a-positive cells in mTCR antibody-positive cells (ie, TCR-positive cells) was analyzed. The analysis results are shown in the figure. Figure 4 As shown, there was no obvious increase in degranulation levels after incubation of TCR-NKT, CD8αβ-TCR NKT, and CD8αα-TCR NKT with MAGE-A4 negative cells; TCR-NKT, CD8αβ-TCRNKT, and CD8αα-TCR NKT could all be activated by MAGE-A4 / HLA-A02:01 double-positive cells; and the CD107a+ ratio of CD8αβ-TCR NKT and CD8αα-TCR NKT after stimulation by double-positive target cells was significantly higher than that of TCRNKT cells.

[0127] (2) In vitro target cell killing assay Experimental purpose and principle: In vitro cell killing experiments used HLA-A02:01+ / MAGE-A4+ [A375 (human malignant melanoma cells), NCI-H1755 (human lung cancer cells), NUGC-4 overexpressed MAGE-A4 (human gastric cancer cells), OE19 overexpressed MAGE-A4 (human esophageal cancer cells), T98G overexpressed MAGE-A4 (human brain glioblastoma multiforme cells)] as positive target cells; HLA-A02:01+ / MAGE-A4- [T98G (human brain glioblastoma multiforme cells)] as negative target cells; HLA-A02:01+ / MAGE-A4- [NUGC-4 (human gastric cancer cells)] as negative target cells; and evaluated the in vitro specific killing ability of each TCR-NKT cell. Among them, the above cells were transduced by lentivirus to obtain target cells that stably expressed firefly luciferase, so the activity of luciferase in the sample can reflect the number of target cells. Co-culture TCR-NKT cells and target cells. When target cells are killed by TCR-NKT, luciferase will be released and quickly inactivated (the half-life of firefly luciferase is about 0.5h). If the target cells are not killed or inhibited by TCR-NKT cells, more luciferase will be produced as the target cells proliferate and luciferase continues to be expressed. Therefore, the killing of target cells by TCR-NKT cells can be detected by the activity of luciferase.

[0128] Brief experimental steps of in vitro cell killing: 1) Centrifuge the above target cells at 500g for 5 minutes at room temperature, discard the supernatant, and use 1640 basal culture medium to re-adjust to 2×105 cells / mL; add 100μL target cells to each well of a 96-well plate; 2) According to the TCR positivity rate and effector-target ratio of the TCR-NKT sample to be tested, add 100 / μL TCR-NKT cells to each well of the 96-well plate and mix with the target cells; then place in a carbon dioxide incubator and incubate for 24 hours; 3) Use a luciferase detection kit to detect the luciferase activity of each well sample.

[0129] Main samples and reagents: Target cells: A375, NCI-H1755, NUGC-4 overexpressing MAGE-A4, OE-19 overexpressing MAGE-A4, T98G overexpressing MAGE-A4, T98G, NUGC-4 Steady-Glo Luciferase Assay System, Promega, Cat. No. E2520 Experimental results: After the TCR-NKT cell samples and a fixed number of target cells (2×104) were mixed at different effector-target ratios (E:T), they were incubated for 24 hours, and then the luciferase activity (RLU) in the samples was detected. Among them, NKT is a control containing only target cells. Since the enzyme activity can reflect the number of target cells in the sample, the killing / inhibition ability of different TCR NKT cells on target cells can be obtained by the change of luciferase activity in the sample. The lower the luciferase activity reading (RLU), the more target cells are killed.

[0130] like Figure 5 As shown in the figure, all TCR NKT cell samples can effectively kill double-positive target cells, and there is no obvious killing when co-incubated with negative target cells or single-negative target cells. Among them, CD8αβ-TCR NKT and CD8αα-TCR NKT cells have stronger killing ability against double-positive target cells than TCR NKT cells.

[0131] (3) Repeated stimulation proliferation experiment Experimental purpose and principle: Target cells (A375) treated with mitomycin were mixed with CD8αβ-TCR NKT, CD8αα-TCR NKT, and TCR NKT cells, respectively. After multiple stimulations, the three types of TCR NKT cells and target cells were co-cultured to determine the proliferation capacity of different TCR NKT cells after continuous stimulation by target cells.

[0132] Experimental steps: 7×10 A375 cells were taken 6 cells, 500 g, room temperature, centrifugation for 5 min; The density was adjusted to 2E5 cells / mL with complete medium, and 5 μL of Mitomycin stock solution (1 μg / μL) was added and mixed, and then cultured for 24 hours before use.

[0133] Take the A375-Mitomycin cells after treatment for 24 hours, centrifuge at 500g to change the medium, wash with PBS 6 times, resuspend the A375-Mitomycin cells in X-VIVO medium, count and adjust the density to 6E6 cells / mL for later use.

[0134] Take 3×10 5TCR-NKT cells were transferred into 24-well plates, and 50 μL of A375-Mitomycin cells were added to each well of TCR-NKT to make the effector-target ratio E:T = 1:1. X-VIVO complete medium was added to the final culture volume of 500 μL, mixed, cultured at 37°C, 5% CO2 for 72 hours and counted, and target cells (A375, SW480) were treated with Mitomycin again, and the above steps were repeated to draw an amplification curve.

[0135] Main samples and reagents: Mitomycin C, MCE, Cat. NO.HY-113061; Target cell A375 Experimental results: Figure 6 As shown, the three groups of TCR-NKT cell samples can be effectively expanded after repeated stimulation. After the target cells are stimulated for 6 times, the expansion capacity of CD8αβ-TCR NKT and CD8αα-TCR NKT cells is strong. The proliferation ability of TCR NKT cells after being stimulated by target cells is closely related to the long-term prognosis of patients. Therefore, TCR-NKT with CD8αβ or CD8αα can be considered to have stronger potential for long-term proliferation and tumor cell elimination.

[0136] (4) In vitro killing experiment after repeated stimulation Experimental purpose and principle: The three types of TCR NKT cells were repeatedly stimulated twice by A375 target cells, and the proliferation of TCR NKT cells was used to test the killing function of A375 cells. Among them, the above cells were transduced by lentivirus to obtain target cells that stably expressed firefly luciferase. The TCR NKT cells stimulated twice were co-cultured with the target cells, and the killing of target cells by TCR NKT after target cell stimulation was detected by the expression of luciferase.

[0137] Brief experimental steps of killing experiment: Same as above. Main samples and reagents: Target cells A375.

[0138] Experimental results: Figure 7 As shown in the figure, CD8αβ-TCR NKT, CD8αα-TCR NKT and simple TCR NKT cells still maintained the ability to kill A375 cells after being stimulated twice by target cells ( Figure 7 ), but TCR NKT cells with CD8αα or CD8αβ can better maintain the ability to kill target cells.

[0139] Example 6 In vivo animal experiment Objective and principle of the experiment: 3×106 A375 tumor cells were injected subcutaneously into 6-week-old NCG mice to construct a melanoma mouse tumor model. TCR-NKT cells were then injected, and the tumor volume was measured regularly. The survival status and body weight changes were recorded to compare the inhibition of tumor cells in each TCR-NKT experimental group.

[0140] Simple experimental steps: 3×106 A375 cells were injected subcutaneously into each experimental mouse; the tumor volume was measured every 3 days to observe whether the tumor was formed normally; after the tumor was formed and the tumor volume reached 80mm3, TCR-NKT cells were injected into the mouse, with each TCR+ cell volume of 5×106 / 200μL, and control NT cells and PBS groups were set up, with 5 experimental mice in each group; the tumor volume was measured every 3 days, weighed and the survival rate was calculated.

[0141] Experimental results: CD8αβ-TCR NKT targeting MAGE-A4, CD8αα-TCR NKT and simple TCR NKT all had significant inhibitory effects on tumors; CD8αβ-TCR NKT and CD8αα-TCR NKT had significantly better tumor inhibition effects than simple TCR NKT, and there was no significant difference in the effects on mouse body weight among the three groups, that is, there was no significant difference in toxicity to mice ( Figure 8 ).

[0142] Example 7 In vivo animal experiment Objective and principle of the experiment: TCR T and CD8αβ-TCR T targeting MAGE-A4 were transferred into αβT cells respectively to construct two T cell preparations, TCR T and CD8αβ-TCR T, and then the T98G MAGE-A4-overexpressing (HLA-A02:01+ and MAGE-A4+) transplanted tumor mouse model was treated to evaluate whether the addition of CD8αβ could enhance the anti-tumor effect of TCR targeting MAGE-A4.

[0143] Simple experimental steps: T98G overexpressing MAGE-A4 (HLA-A02:01+ and MAGE-A4+) tissue blocks (20mm3 / mouse) were subcutaneously transplanted into each experimental mouse; MOCK T cells, TCR T cells targeting MAGE-A4, or CD8αβ-TCR T cells targeting MAGE-A4 were started on the third day after inoculation. Each mouse was intravenously infused with 5*106 T cells, and each group had 6 experimental mice. Tumor volume was measured every 3 days. Experimental results: The results are as follows Fig. 9 As shown: Consistent with TCR NKT, CD8αβ-TCR T has a stronger anti-tumor effect than TCR T for HLA-A02:01+ and MAGE-A4+ solid tumors.

[0144] The present invention illustrates the process method of the present invention through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned process steps, that is, it does not mean that the present invention must rely on the above-mentioned process steps to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of the raw materials selected by the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.

Claims

1. A T cell receptor, comprising a TCRα domain, a TCRβ domain, a CD8α domain and / or a CD8β domain, and a linker domain connecting the domains, It is characterized in that The sequence of the CD8α domain is at least 90% identical to SEQ ID NO:20, and the sequence of the CD8β domain is at least 90% identical to SEQ ID NO:

24.

2. The T cell receptor according to claim 1, It is characterized in that The T cell receptor comprises a TCRα domain, a TCRβ domain, a CD8α domain and a CD8α domain, and a linker domain connecting the domains, or the T cell receptor comprises a TCRα domain, a TCRβ domain, a CD8α domain and a CD8β domain, and a linker domain connecting the domains.

3. The T cell receptor according to claim 2, It is characterized in that The TCRα domain includes the TCR Vα region, the TCR Jα region and the TCR mCα region in sequence, the TCRβ domain includes the TCR Vβ region, the TCR Dβ region, the TCR Jβ region and the TCR mCβ region in sequence, or the TCRα domain is composed of the TCR Vα region, the TCR Jα region and the TCR mCα region in sequence, and the TCRβ domain is composed of the TCR Vβ region, the TCR Dβ region, the TCR Jβ region and the TCR mCβ region in sequence.

4. The T cell receptor according to claim 3, It is characterized in that The sequence of the TCR Vα region is shown in SEQ ID NO:2, the sequence of the TCR Jα region is shown in SEQ ID NO:4, the sequence of the TCR mCα region is shown in SEQ ID NO:6 and / or the sequence of the TCR Vβ region is shown in SEQ ID NO:10, the sequence of the TCR Dβ region is shown in SEQ ID NO:12, the sequence of the TCR Jβ region is shown in SEQ ID NO:14, and the sequence of the TCR mCβ region is shown in SEQ ID NO:

16.

5. The T cell receptor according to any one of claims 1 to 4, It is characterized in that The sequence of the CD8α domain is shown in SEQ ID NO:20, and the sequence of the CD8β domain is shown in SEQ ID NO:

24.

6. The T cell receptor according to any one of claims 1 to 4, It is characterized in that in, The nucleotide sequences of CDR1, CDR2 and CDR3 contained in the TCRα domain are ACCTCCGAGAACAACTACTAC (SEQ ID NO: 25), AGGAGGCCTACAAGCAACAGAAC (SEQ ID NO: 26), and GCCACCCACAGCGGCGCCGGCAGCTACCAGCTGACC (SEQ ID NO: 27), respectively; The nucleotide sequences of CDR1, CDR2 and CDR3 contained in the TCRβ domain are AGCGAGCACAATCGG (SEQ ID NO: 31), TTCCAGAATGAAGCCCAG (SEQ ID NO: 32), and GCCAGCTCTGCTCCTGGCTATAACGAGCAGTTT (SEQ ID NO: 33), respectively.

7. The T cell receptor according to any one of claims 1 to 4, It is characterized in that in, The amino acid sequences of CDR1, CDR2 and CDR3 contained in the TCRα domain are TSENNYY (SEQ ID NO: 28), QEAYKQQN (SEQ ID NO: 29), and ATHSGAGSYQLT (SEQ ID NO: 30), respectively; wherein, the amino acid sequences of CDR1, CDR2 and CDR3 contained in the TCRβ domain are SEHNR (SEQ ID NO: 34), FQNEAQ (SEQ ID NO: 35), and ASSAPGYNEQF (SEQ ID NO: 36), respectively.

8. An isolated polynucleotide, It is characterized in that The polynucleotide encodes the T cell receptor according to any one of claims 1-7.

9. The polynucleotide according to claim 8, It is characterized in that The nucleotide sequence encoding the CD8α domain is at least 85% identical to SEQ ID NO:

19.

10. The polynucleotide according to claim 8, It is characterized in that The nucleotide sequence encoding the CD8β domain is at least 85% identical to SEQ ID NO:

23.

11. A polynucleotide according to any one of claims 8 to 10, It is characterized in that The TCR Vα region comprises the nucleotide sequence shown in SEQ ID NO: 1, the TCR Jα region comprises the nucleotide sequence shown in SEQ ID NO: 3, and the TCR mCα region comprises the nucleotide sequence shown in SEQ ID NO:

5.

12. A polynucleotide according to any one of claims 8 to 10, It is characterized in that The TCR Vβ region comprises the nucleotide sequence shown in SEQ ID NO:9, the TCR Dβ region comprises the nucleotide sequence shown in SEQ ID NO:11, the TCR Jβ region comprises the nucleotide sequence shown in SEQ ID NO:13, and the TCR mCβ region comprises the nucleotide sequence shown in SEQ ID NO:

15.

13. Carrier, It is characterized in that The vector comprises the polynucleotide according to any one of claims 8 to 12.

14. The vector according to claim 13, It is characterized in that The vector is selected from plasmid, retroviral vector and lentiviral vector, transposon vector, ssDNA, dsDNA.

15. Cells, It is characterized in that The cell comprises the vector according to any one of claims 13-14.

16. Cells, It is characterized in that The cell presents the T cell receptor according to any one of claims 1-7.

17. Cells, It is characterized in that The cell comprises the T cell receptor according to any one of claims 1-7.

18. The cell according to any one of claims 15 to 17, It is characterized in that The cells are NKT cells, lymphocyte T cells.

19. A method for preparing the T cell receptor according to any one of claims 1 to 7, It is characterized in that The method comprises: 1) incubating the cell according to any one of claims 15 to 18; 2) Purifying the T cell receptor. 20.T cell receptor, It is characterized in that The T cell receptor is prepared by the method according to claim 19.

21. A composition comprising one or more of the following: 1) The T cell receptor according to any one of claims 1 to 7; 2) A polynucleotide according to any one of claims 8 to 12; 3) The vector according to any one of claims 13-14; 4) The cell according to any one of claims 15-18.

22. Use of the T cell receptor according to any one of claims 1 to 7, the polynucleotide according to any one of claims 8 to 12, the vector according to any one of claims 13 to 14, or the cell according to any one of claims 15 to 18 in the preparation of a composition for treating cancer.

23. The use according to claim 22, It is characterized in that The cancer is selected from melanoma, lung cancer, gastric cancer, esophageal cancer, and human brain glioblastoma multiforme.

24. Use of CD8α and CD8β in preparing a composition for improving the killing ability of T cells, It is characterized in that CD8α and CD8β are constructed into a T cell receptor or CD8α and CD8β are co-expressed with a T cell receptor in T cells, the sequence of the CD8α domain being at least 90% identical to SEQ ID NO: 20, and the sequence of the CD8β domain being at least 90% identical to SEQ ID NO:

24.

25. The use according to claim 24, It is characterized in that The CD8α and CD8β are constructed into a T cell receptor, which comprises a TCRα domain, a TCRβ domain, a CD8α domain and / or a CD8β domain, and a linker domain connecting the domains.